Parallel Fluidics Accelerates Commercial Push for High-Throughput LNP Screening Array

Parallel Fluidics, a microfluidics and lab automation specialist, used the past week to intensify promotion of its LNP Screening Array, highlighting speed and integration with existing liquid handlers. The company is positioning the platform as a faster alternative to dedicated lipid nanoparticle instruments that can require long run times and risk evaporation-related data issues.

The LNP Screening Array is designed to complete high-throughput LNP formulations in minutes directly on standard liquid-handling decks, aiming to deliver consistent particle size and polydispersity index across full screening sets. By leveraging existing automation infrastructure, Parallel Fluidics is emphasizing lower adoption friction and reduced capital expenditure for biopharma, CDMOs, and research labs.

Commercially, the firm reported strong engagement around its presence at SLAS 2026, where it held workflow discussions and set up follow-up demonstrations intended to convert interest into pilot evaluations. In parallel, it is executing a focused outreach campaign in the Boston biopharma cluster, offering on-site demos to showcase automated LNP formulation on customers’ own instruments.

A key part of the go-to-market strategy is a complimentary “Starter Array,” an entry-level offering meant to lower barriers to trial and accelerate product-led growth. The company is encouraging both SLAS contacts and non-attendees to request these starter kits, using them as a funnel to build a recurring consumables and upgrades revenue base.

Technically, the LNP Screening Array is presented as a configurable microfluidic platform supporting staggered herringbone, flow focusing, and T-junction mixing geometries, allowing users to tune particle size and PDI for mRNA and nanoparticle-based drug delivery applications. If customers validate the promised throughput and reproducibility gains, the solution could strengthen Parallel Fluidics’ position in LNP-based drug discovery and RNA-delivery workflows.

While no sales figures were disclosed, the week’s activity underscores an early but deliberate commercialization push built around conference visibility, regional demos, and capital-efficient integration. Overall, it was a strategically important week as Parallel Fluidics worked to expand awareness, drive pilots, and deepen its foothold in the high-throughput LNP screening and lab automation market.